The SERPINE1 gene variant kept the Amish population alive for 10 years.

A genetic mutation that appeared in the Amish population 10 years ago seems to be enough to keep them alive for another 10 years and make them less likely to develop diabetes.
results were published in the journal Science Advances.
previous research has found that a gene called SERPINE1 produces the aging-promoting protein PAI-1.
, however, the wrong variant of the gene appeared in a six-generation Amish group and produced half of the aging protein in the people who carried the mutation.
researchers want to know if this is likely to be associated with longer life spans in people who carry it.
, Douglas Vaughan of Northwestern University and his team studied the genes of 177 members of the Amish community of old Indiana.
43 of them carried at least one copy of the gene variant.
team analyzed the DNA of these people, as well as other signs of aging, such as insulin tolerance associated with diabetes and the length of the telomeres, a protective cap at the end of the chromosome.
they also identified 221 deceased relatives who carried the gene variant and analyzed their longevity.
study found that people who carried at least one copy of the gene lived an average of 10 years longer, with the median age of death being 85 years.
at fast, people with the gene variant had 30 percent lower insulin levels, a sign of slowing aging.
the carriers of the mutation did not develop diabetes, and 7 percent of those without the mutation had diabetes.
" the study adds evidence to the possibility of longer life and healthy life expectancy in humans.
," says Brian Kennedy from the National University of Singapore.
the telomere chromosome cap shaded by 10% in people with the SERPINE1 gene variant.
These protective caps become shorter whenever the cells divide.
and shorter telomeres are signs that human cells are running out and aging.
targetING PAI-1 drugs are already in development and include a drug that may prevent or relieve hair loss.
"There will be countless groups that may benefit from the drug that inhibits PAI-1."
," Vaughan said.
.